Pacific Biosciences of California (NASDAQ:PACB) will post its quarterly earnings results after the market closes on Monday, August 3rd. Analysts expect Pacific Biosciences of California to post earnings of ($0.19) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.
Pacific Biosciences of California (NASDAQ:PACB) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.05). Pacific Biosciences of California had a negative net margin of 58.35% and a negative return on equity of 131.21%. The company had revenue of $15.60 million during the quarter, compared to analyst estimates of $20.10 million. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ PACB opened at $3.73 on Friday. Pacific Biosciences of California has a 52 week low of $2.20 and a 52 week high of $5.94. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.16 and a current ratio of 1.28. The company has a 50-day moving average price of $3.74 and a two-hundred day moving average price of $3.72.
Several research analysts have recently issued reports on PACB shares. Piper Sandler decreased their price objective on shares of Pacific Biosciences of California from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Zacks Investment Research downgraded shares of Pacific Biosciences of California from a “hold” rating to a “sell” rating and set a $4.00 price target for the company. in a research report on Wednesday, July 1st. BidaskClub upgraded shares of Pacific Biosciences of California from a “sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $5.00 target price on shares of Pacific Biosciences of California in a research report on Wednesday, June 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. Pacific Biosciences of California currently has a consensus rating of “Buy” and a consensus price target of $5.50.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.
Recommended Story: Resistance Level
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.